AI주식인사이트AI Stock Insight
D

오름테라퓨틱

475830KOSDAQ

36.5 / 100

Reference Date: 2026-10-23

Financial Score12.0 / 40
News Sentiment12.5 / 25
Momentum2.0 / 20
Disclosure10.0 / 15
AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Plunged 66.8% over the past month, with no recent news.

Company InformationBased on 2025 Annual Report

Business Overview

Orm Therapeutics is a clinical-stage biotech company developing antibody-based targeted protein degradation (TPD²®) therapies to treat cancer. Its key candidates, ORM-5029 and ORM-1153, target HER2-positive breast cancer and hematologic malignancies, with ORM-5029 in Phase 1 trials and ORM-1153 preparing for IND submission in 2026. TPD² combines ADC technology to deliver protein degraders selectively to cancer cells, minimizing off-target effects and enhancing therapeutic efficacy.

Number of Employees

21people

Average Salary

174.2M KRW

Score Calculation Basis

Detailed Financial Score

PER
—Industry Average 15.004.0Point
PBR
2.80Industry Average 1.200.0Point

2.3x industry avg (risky)

ROE
-33.22Industry Average 8.000.0Point

Well below industry avg

Debt Ratio
17.44Industry Average 100.008.0Point

Half of industry avg (excellent)

Trend 2024~20250.0 / 10 points
Revenue Growth Rate
0.0 / 3

Avg ▼99.9% (1-year basis)

Operating Profit Growth Rate
0.0 / 3

Avg ▼521.0% (1-year basis)

ROE Trend
0.0 / 4

Detailed News Sentiment

0 totalPositive 0Neutral 0Negative 0

Detailed Momentum

52-week position1.0Point

Near 52w low (0%, downtrend)

Current 16,840Won52-week high 143,70052-week low 15,710
1-month return0.0Point

1m -66.85% (strong drop)

Volume trend1.0Point

Volume dry-up

Detailed Disclosure

3 totalPositive 0Neutral 3Negative 0
  • Neutral[기재정정]주주총회소집공고2026-10-22
  • Neutral주식등의대량보유상황보고서(일반)2026-10-21
  • Neutral주주총회소집공고2026-10-08